FATE - Fate Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
FATE price evolution
FATE
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $52.09 | $136.5 | $57.05 | |
| Short term investments | $267.96 | $262.22 | $273.31 | |
| Net receivables | $4.13 | $1.05 | $0.86 | $1.83 |
| Inventory | ||||
| Total current assets | $310.29 | $319.39 | $394.38 | $331.54 |
| Long term investments | $47.16 | $7.59 | $0.98 | |
| Property, plant & equipment | $140.83 | $147.08 | $152.74 | $158.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $209.43 | $175.52 | $174.68 | |
| Total investments | $315.12 | $269.82 | $274.29 | |
| Total assets | $494.97 | $528.82 | $569.89 | $506.22 |
| Current liabilities | ||||
| Accounts payable | $6.35 | $5.5 | $6.76 | $4.72 |
| Deferred revenue | $0.16 | $0.69 | ||
| Short long term debt | $6.64 | $6.4 | $6.18 | |
| Total current liabilities | $37.42 | $34.79 | $45.37 | $39.09 |
| Long term debt | $93.92 | $95.67 | $97.36 | |
| Total noncurrent liabilities | $97.04 | $98.41 | $98.71 | |
| Total debt | $100.56 | $102.07 | $103.54 | |
| Total liabilities | $132.64 | $131.84 | $143.78 | $137.8 |
| Shareholders' equity | ||||
| Retained earnings | -$1345.84 | -$1298.16 | -$1259.74 | -$1211.73 |
| Other shareholder equity | $0.83 | -$0.42 | -$0.19 | $0.01 |
| Total shareholder equity | $396.98 | $426.12 | $368.42 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $57.05 | $76.56 | $148.81 | $182.57 |
| Short term investments | $273.31 | $374.89 | $482.33 | $315.57 |
| Net receivables | $1.83 | $38.48 | $8.68 | $5.51 |
| Inventory | ||||
| Total current assets | $331.54 | $502.07 | $633.41 | $494.32 |
| Long term investments | $0.98 | $4.94 | $100.66 | |
| Property, plant & equipment | $158.51 | $176.09 | $162.25 | $99.39 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $174.68 | $203.49 | $288.04 | $128.13 |
| Total investments | $274.29 | $379.84 | $582.99 | $315.57 |
| Total assets | $506.22 | $705.56 | $921.46 | $622.46 |
| Current liabilities | ||||
| Accounts payable | $4.72 | $8.27 | $8.61 | $6.28 |
| Deferred revenue | $0.69 | $42.23 | $48.61 | $67.17 |
| Short long term debt | $6.18 | $5.63 | $5.58 | $3.35 |
| Total current liabilities | $39.09 | $114.05 | $81.28 | $85.56 |
| Long term debt | $97.36 | $103.71 | $109.24 | $93.94 |
| Total noncurrent liabilities | $98.71 | $107.57 | $161.33 | $152.45 |
| Total debt | $103.54 | $109.34 | $114.82 | $97.3 |
| Total liabilities | $137.8 | $221.62 | $242.62 | $238.01 |
| Shareholders' equity | ||||
| Retained earnings | -$1211.73 | -$1050.8 | -$769.08 | -$556.93 |
| Other shareholder equity | $0.01 | -$1.85 | -$0.76 | $0.07 |
| Total shareholder equity | $368.42 | $483.94 | $678.84 | $384.44 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.77 | $1.93 | $1.68 | |
| Cost of revenue | ||||
| Gross Profit | $6.77 | $1.93 | $1.68 | |
| Operating activities | ||||
| Research & development | $34.6 | $32.14 | $31.82 | |
| Selling, general & administrative | $17.25 | $20.86 | $17.93 | |
| Total operating expenses | $51.85 | $52.99 | $49.75 | |
| Operating income | -$45.08 | -$51.07 | -$48.08 | |
| Income from continuing operations | ||||
| EBIT | -$38.43 | -$48 | -$44.12 | |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$38.43 | -$48 | -$44.12 | |
| Income (for common shares) | -$38.43 | -$48 | -$44.12 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $63.53 | $96.3 | $55.85 | $31.43 |
| Cost of revenue | ||||
| Gross Profit | $63.53 | $96.3 | $55.85 | $31.43 |
| Operating activities | ||||
| Research & development | $172.6 | $320.45 | $215.52 | $125.62 |
| Selling, general & administrative | $81.45 | $84.23 | $57.32 | $33.9 |
| Total operating expenses | $254.04 | $404.69 | $272.84 | $159.52 |
| Operating income | -$190.51 | -$308.39 | -$216.99 | -$128.09 |
| Income from continuing operations | ||||
| EBIT | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| Income (for common shares) | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$38.43 | -$48 | -$44.12 | |
| Operating activities | ||||
| Depreciation | $4.72 | $4.82 | $4.88 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.63 | $10.98 | $9.47 | |
| Total cash flows from operations | -$32.31 | -$33.35 | -$36.64 | |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$0.09 | -$0.18 | |
| Investments | -$53.32 | $17.4 | $45.53 | |
| Total cash flows from investing | -$10.6 | -$53.37 | $17.31 | $45.35 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.67 | $75.49 | -$0.18 | |
| Net borrowings | ||||
| Total cash flows from financing | $96.76 | $1.27 | $95.49 | -$0.18 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$8.91 | -$84.41 | $79.45 | $8.54 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$160.93 | -$281.72 | -$212.15 | -$173.39 |
| Operating activities | ||||
| Depreciation | $18.28 | $13.76 | $5.85 | $3.09 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $43.46 | $78.73 | $54.36 | $30.75 |
| Total cash flows from operations | -$132.26 | -$248.21 | -$162.87 | -$39.23 |
| Investing activities | ||||
| Capital expenditures | -$6.15 | -$35.57 | -$50.7 | -$4.93 |
| Investments | $118.82 | $202.32 | -$273.32 | -$156.14 |
| Total cash flows from investing | $112.67 | $166.75 | -$324.02 | -$161.08 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.09 | $9.21 | $432.45 | $282.35 |
| Net borrowings | ||||
| Total cash flows from financing | $0.09 | $9.21 | $453.13 | $282.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$19.51 | -$72.25 | -$33.76 | $82.53 |
News
Fundamentals
| Market cap | $169.69M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 113.88M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.37 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.29 |
| Quick ratio | N/A |